子分类：
- C07C235/02：·带有连接在非环碳原子上的羧酰胺基的碳原子和连接在同一碳架上的单键氧原子
- C07C235/40：·带有连接在除六元芳环以外的环的碳原子上的羧酰胺基的碳原子和连在同一碳架上的单键氧原子
- C07C235/42：·带有连接在六元芳环碳原子上的羧酰胺的碳原子和连在同一碳架上的单键氧原子
- C07C235/68：·至少1个羧酰胺基的氮原子连接在非环碳原子和至少有一个邻位氢原子被取代的六元芳环碳原子上
- C07C235/70：·带有连接在同一碳架上的羧酰胺基的碳原子和双键氧原子
- C07C235/86：·含有至少1个羧酰胺基的氮原子季铵化
- C07C235/88：·含有至少1个羧酰胺基的氮原子进一步被酰化
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 281 | UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS | PCT/US2001/044326 | 2001-11-29 | WO02044398A2 | 2002-06-06 | |
| Universal supports for oligonucleotide synthesis include a support material represented by the formula (I). In this formula, substituent A is selected from H, alkyl, aryl, or a polymeric or silica base material; substituent B is selected from acyl, aroyl or a polymeric or silica base material; and substituent C is selected from a dimethoxytrityl group or a protecting group removable under acidic or neutral conditions. For the supports, one of substituents A or B constitutes the polymeric or silica base material. In use, an oligonucleotide is attached to the support at substituent C. | ||||||
| 282 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | PCT/EP2001/002016 | 2001-02-22 | WO01062709A2 | 2001-08-30 | |
| The invention relates to the use of compounds of formula (I), wherein n = 0 - 3; R<1>, R<2> = H, alkyl, aryl, heteroaryl, acyl; R<3> = H, halogen, alkyl, aryl, heteroaryl, arylalkyl, acyl, CN, NO2, R<4>-X-; R<4> = H, alkyl, aryl, heteroaryl, aralkyl, acyl; X = NH, O, S, SO2, NHSO2, OSO2, and A, B, C = organic groups. The inventive compounds are used for the prophylaxis and the therapeutic treatment of infectious processes, especially of infectious processes caused by parasites. The invention further relates to medicaments that contain the inventive compounds. | ||||||
| 283 | HSV PRIMASE INHIBITORS | PCT/CA2000/000324 | 2000-03-23 | WO00058270A3 | 2001-03-01 | |
| The invention provides compounds of formula (1) that are active against the HSV primase enzyme: wherein R1 is hydroxy or amino; R2 is hydrogen, halo, (C1-4)alkyl or (C1-4)alkoxy; R3 is hydrogen, halo, (C1-4)alkyl, (C1-4)alkoxy, amino or azido; R4 has the same significance as R2; R5 is hydrogen or (C1-4)alkyl; and R is (C1-7)alkyl, (C3-6)cycloalkyl, {phenyl(C1-7)alkyl}, {phenyl(C1-7)alkoxy}, {{(monocyclic heterocyclo)-{(C1-7)alkoxy}}, CH(W)C(O){O-(C1-4)alkyl} wherein W is hydrogen or (C1-7)alkyl, or (a) wherein Y is hydrogen or (C1-7)alkyl, and Z is (C1-7)alkyl, (C3-6) cycloalkyl, {(C3-6)cycloalkyl}-{(C1-7)alkyl}, phenyl(C1-7)alkyl or {{(monocyclic heterocyclo)-{(C1-7)alkyl}}, or Y and Z together with the nitrogen atom to which they are attached represent, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl or 1-(4-methylpiperazinyl); with the provisos that (1) when R is CH(W)C(O)-{O-(C1-4)alkyl} as defined herein, then R5 is hydrogen; and (2) at least one of R2, R3 and R4 is other than hydrogen. | ||||||
| 284 | PROCESS FOR PREPARING ACIDS VIA ALPHA-CHLOROEPOXY ESTERS | PCT/US2000/021394 | 2000-08-04 | WO01010822A1 | 2001-02-15 | |
| This invention relates to a method for preparing certain acids of formula (I) via a chloroepoxy ester, which are useful as phosphodiesterase 4 inhibitors. | ||||||
| 285 | MONOMERS AND NETWORK POLYMERS OBTAINED THEREFROM | PCT/GB1999/002416 | 1999-07-26 | WO00006533A2 | 2000-02-10 | |
| A compound of formula (I) where R<1> is CH and R<6> is a bond, or R<1> and R<6> together form an electron withdrawing group; R<2> and R<3> are independently selected from (CR<7>R<8>)n, or a group CR<9>R<10>, -(CR<7>R<8>CR<9>R<10>)- or -(CR<9>R<10>CR<7>R<8>)- where n is 0,1 or 2, R<7> and R<8> are independently selected from hydrogen or alkyl, and either one of R<9> or R<10> is hydrogen and the other is an electron withdrawing group, or R<9> and R<10> together form an electron withdrawing group, and R<4> and R<5> are independently selected from CH or CR<11> where R<11> is an electron withdrawing group; the dotted lines indicate the presence or absence of a bond, and X<1> is a group CX<2>X<3> where the dotted line bond to which it is attached is absent and a group CX<2> where the dotted line bond to which it is attached is present, Y<1> is a group CY<2>Y<3> where the dotted line bond to which it is attached is absent and a group CY<2> where the dotted line bond to which it is attached is present, and X<2>, X<3>, Y<2> and Y<3> are independently selected from hydrogen and fluorine; R<16> is a bridging group of valency r and r is an integer of 2 or more, subject to the following provisos: (i) that at least one of (a) R<1> and R<6> or (b) R<2> and R<3> or (c) R<4> and R<5> includes an electron withdrawing group. These compounds are useful in the production of network polymers, for example for coatings or binders. | ||||||
| 286 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | PCT/US1998/022309 | 1998-10-20 | WO99020599A1 | 1999-04-29 | |
| The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders. | ||||||
| 287 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE | PCT/US1998/017327 | 1998-08-24 | WO99011606A2 | 1999-03-11 | |
| The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) and (II) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM). | ||||||
| 288 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1- (protected hydroxy)-propane salts and methods of making the same | US17987469 | 2022-11-15 | US12122735B2 | 2024-10-22 | Jennifer Elizabeth Albaneze-Walker |
| Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided. | ||||||
| 289 | Amorphous Solid Succinylated 3-(Fatty Acid Amido)-2-Hydroxy-1-(Protected Hydroxy)-Propane Salts and Methods of Making the Same | US17987469 | 2022-11-15 | US20230192597A1 | 2023-06-22 | Jennifer Elizabeth Albaneze-Walker |
| Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided. | ||||||
| 290 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same | US17079129 | 2020-10-23 | US11530179B2 | 2022-12-20 | Jennifer E. Albaneze-Walker |
| Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided. | ||||||
| 291 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | US17079129 | 2020-10-23 | US20210147344A1 | 2021-05-20 | Jennifer E. Albaneze-Walker |
| Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided. | ||||||
| 292 | N-acylethanolamide derivatives and uses thereof | US16349548 | 2017-10-12 | US10933037B2 | 2021-03-02 | Andrew D. Levin |
| The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto. | ||||||
| 293 | Curing agents and degradable polymers and composites based thereon | US14781242 | 2014-04-18 | US10308594B2 | 2019-06-04 | Bing Qin; Xin Li; Bo Liang |
| The present invention provides, among others, compounds of Formula (I) or a salt thereof, methods for making these compounds, degradable polymers and reinforced composites made therefrom, and methods for degrading and/or recycling the degradable polymers and reinforced composites. | ||||||
| 294 | Graphene quantum dots and method of making | US14261936 | 2014-04-25 | US09637443B2 | 2017-05-02 | Julia Xiaojun Zhao; Xu Wu |
| A method for forming a graphene quantum dot product includes adding an organic starting material to a vessel and heating the organic starting material to a temperature within 20° C. of the organic starting material's boiling temperature for a time no longer than ten minutes to form graphene quantum dots. A method for sensing a graphene quantum dot includes forming a graphene quantum dot, exciting the graphene quantum dot with light having a first wavelength, measuring light emitted by the excited graphene quantum dot at a second wavelength different from the first wavelength. A graphene quantum dot includes carbon atoms and nitrogen atoms where the nitrogen atoms are present within the graphene quantum dot at a level between 6.0% and 11.0% of a level of carbon atoms present in the graphene quantum dot. | ||||||
| 295 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | US14518300 | 2014-10-20 | US09259403B2 | 2016-02-16 | Rahul Surana; Mahendra G. Dedhiya |
| The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | ||||||
| 296 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | US13678802 | 2012-11-16 | US08987262B2 | 2015-03-24 | Christine Leaute-Labreze; Eric Dumas De La Roque; Alain Taieb; Jean-Benoit Thambo |
| The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas. | ||||||
| 297 | Cysteine protease inhibitors | US13139962 | 2009-12-18 | US08853281B2 | 2014-10-07 | Susana Ayesa; Anna Karin Belfrage; Bjorn Classon; Urszula Grabowska; Ellen Hewitt; Vladimir Ivanov; Daniel Jönsson; Pia Kahnberg; Peter Lind; Magnus Nilsson; Lourdes Odén; Mikael Pelcman; Horst Wähling |
| Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain. | ||||||
| 298 | Concurrent therapy regime/regimen for the treatment of acne related diseases | US12992425 | 2009-05-18 | US08853275B2 | 2014-10-07 | Jean-Charles Dhuin; Nabil Kerrouche; Stéphanie Arsonnaud; Pascale Soto |
| A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy. | ||||||
| 299 | Additive for preserving the fluidity of fluids containing gas hydrates | US12293922 | 2007-03-16 | US08821754B2 | 2014-09-02 | Martin Hellsten; Hans Oskarsson |
| The present invention relates to the use of a specific group of alkoxylated and/or acylated non-quaternary nitrogen-containing compounds as anti-agglomerants for gas hydrates.The invention also relates to a method for inhibiting the agglomeration of gas hydrates in a conduit, and compositions comprising the gas hydrate anti-agglomerant, a corrosion inhibitor and/or a paraffin deposition inhibitor. | ||||||
| 300 | Method and composition for prolonging analgesic effect of local anesthetic | US13340330 | 2011-12-29 | US08779003B2 | 2014-07-15 | Yu-Chun Hung |
| Disclosed herein is a method for prolonging analgesic effect of a membrane permeable local anesthetic in a subject in need thereof. The method uses cinnamaldehyde as an adjuvant which, when administered prior to or simultaneously with the administration of a local anesthetic, prolongs the analgesic effect of the local anesthetic. Also disclosed herein is a method for providing analgesic effect in a subject in need thereof. The method uses cinnamaldehyde as an analgesic compound which, when administered alone to the subject in an analgesically effective amount, provides the analgesic effect. | ||||||
QQ群二维码
意见反馈
意见反馈